Proparacaine

Generic Name: Proparacaine

Brand Names: Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₂₆N_₂O_₃

CAS Number: 499-67-2

Unique Ingredient Identifier: B4OB0JHI1X

Background: Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.

Indication: Used as a local (ophthalmic) anesthetic.

Associated Conditions: Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Associated Therapies: Local Anaesthesia therapy

Clinical Trials

Safety Study of Lenalidomide/Dexamethasone to Treat Patients With Relapsed or Refractory Multiple Myeloma

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2016-02-26

Last Posted Date: 2022-06-30

Lead Sponsor: Celgene

Target Recruit Count: 22

Registration Number: NCT02692339

Locations: 🇵🇹
Hospital Professor Doutor Fernando Fonseca, E.P.E., Amadora, Portugal
🇵🇹
Hospital Central de Faro, Faro, Portugal
🇵🇹
Fundação Champalimaud, Lisboa, Portugal

and more 9 locations

A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Durvalumab
Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2016-02-19

Last Posted Date: 2023-10-06

Lead Sponsor: Celgene

Target Recruit Count: 56

Registration Number: NCT02685826

Locations: 🇺🇸
Swedish Medical Center, Seattle, Washington, United States
🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
🇨🇦
British Columbia Cancer Agency, Vancouver, British Columbia, Canada

and more 51 locations

Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma

Conditions: Multiple Myeloma in Relapse
Multiple Myeloma

First Posted Date: 2016-01-28

Last Posted Date: 2017-08-28

Lead Sponsor: Dana-Farber Cancer Institute

Registration Number: NCT02666209

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma

Phase 3

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Lenalidomide (Control)
Drug: Lenalidomide
Drug: Carfilzomib
Drug: Dexamethasone

First Posted Date: 2016-01-20

Last Posted Date: 2024-08-15

Lead Sponsor: University of Chicago

Target Recruit Count: 180

Registration Number: NCT02659293

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
Wayne State University - Karmanos Cacner Institute, Detroit, Michigan, United States
🇵🇱
Polish Myeloma Consortium, Poznań, Poland

Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Elotuzumab
Drug: Lenalidomide
Other: autologous PBMC reconstitution
Other: ASCT

First Posted Date: 2016-01-14

Last Posted Date: 2017-08-18

Lead Sponsor: Hearn Jay Cho

Target Recruit Count: 15

Registration Number: NCT02655458

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

Smart Start: A Phase II Study of Rituximab, Lenalidomide, and Ibrutinib

Phase 2

Completed

Conditions: Diffuse Large B-Cell Lymphoma Unclassifiable

Interventions: Drug: Cyclophosphamide
Drug: Doxorubicin Hydrochloride
Drug: Etoposide
Drug: Ibrutinib
Drug: Lenalidomide
Drug: Prednisone
Biological: Rituximab
Drug: Vincristine Sulfate

First Posted Date: 2015-12-21

Last Posted Date: 2024-03-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 60

Registration Number: NCT02636322

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma

Phase 2

Completed

Conditions: Mantle Cell Lymphoma
Untreated

Interventions: Drug: Lenalidomide
Drug: R-CHOP
Drug: high-dose cytarabine (HIDAC)

First Posted Date: 2015-12-17

Last Posted Date: 2023-11-08

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 49

Registration Number: NCT02633137

Locations: 🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 4 locations

A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma

Phase 1

Completed

Conditions: Lymphoma, Follicular

Interventions: Drug: Atezolizumab (MPDL3280A) [TECENTRIQ]
Drug: Lenalidomide
Drug: Obinutuzumab

First Posted Date: 2015-12-16

Last Posted Date: 2022-04-13

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 38

Registration Number: NCT02631577

Locations: 🇺🇸
University Miami, Miami, Florida, United States
🇫🇷
Hopital du Bocage, Dijon, France
🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States

and more 13 locations

R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma

Phase 1

Active, not recruiting

Conditions: Recurrent B-Cell Non-Hodgkin Lymphoma
Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma
Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
Refractory B-Cell Non-Hodgkin Lymphoma
Refractory Transformed Non-Hodgkin Lymphoma
Recurrent Transformed Non-Hodgkin Lymphoma

Interventions: Drug: Carboplatin
Drug: Etoposide
Drug: Ifosfamide
Other: Laboratory Biomarker Analysis
Drug: Lenalidomide
Biological: Rituximab

First Posted Date: 2015-12-11

Last Posted Date: 2024-07-01

Lead Sponsor: Academic and Community Cancer Research United

Target Recruit Count: 30

Registration Number: NCT02628405

Locations: 🇺🇸
Carle Cancer Center NCI Community Oncology Research Program, Urbana, Illinois, United States
🇺🇸
Marshfield Medical Center-Marshfield, Marshfield, Wisconsin, United States
🇺🇸
Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon, New Hampshire, United States

and more 9 locations

Alternating Ixazomib Citrate and Lenalidomide as Maintenance Therapy After Stem Cell Transplant in Treating Patients With Multiple Myeloma

Phase 2

Active, not recruiting

Conditions: Plasma Cell Myeloma
Transplant-Related Carcinoma

Interventions: Drug: Ixazomib Citrate
Other: Laboratory Biomarker Analysis
Drug: Lenalidomide

First Posted Date: 2015-12-02

Last Posted Date: 2024-04-25

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 30

Registration Number: NCT02619682

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy